The PACE-AL trial, sponsored by the Universitetshospitalernes Center for Sygepleje, investigates a multimodal exercise-based intervention aimed at improving the quality of life and physical function of patients undergoing consolidation chemotherapy for acute leukemia. Given the increasing focus on supportive care and rehabilitation in oncology, this study aligns with market trends emphasizing holistic patient management. The collaboration with notable partners such as Novo Nordisk A/S and the Danish Cancer Society enhances credibility and may facilitate future commercialization opportunities. The results could position the intervention as a standard supportive care practice, potentially influencing reimbursement strategies and clinical guidelines.